SEC Form 4 · accession 0000899243-17-007154
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
W. Mark Watson
Director
Period of report
Mar 8, 2017
Accepted (ET)
Mar 10, 2017 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 8, 2017 | M | 300,000 | — | A | 310,000 | D | |
| Common Stock | Mar 8, 2017 | F | 118,800 | $0.34 | D | 191,200 | D | |
| Common StockF3 | Mar 8, 2017 | M | 400,000 | — | A | 591,200 | D | |
| Common Stock | Mar 8, 2017 | F | 158,400 | $0.34 | D | 432,800 | D | |
| Common StockF4 | Mar 8, 2017 | M | 200,000 | — | A | 632,800 | D | |
| Common Stock | Mar 8, 2017 | F | 79,200 | $0.34 | D | 553,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Mar 8, 2017 | M | 300,000 | D | — | — | Common Stock | 300,000 | 0 | D |
| Restricted Stock UnitsF1,F3 | — | Mar 8, 2017 | M | 400,000 | D | — | — | Common Stock | 400,000 | 0 | D |
| Restricted Stock UnitsF1,F4 | — | Mar 8, 2017 | M | 200,000 | D | — | — | Common Stock | 200,000 | 0 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock.
- F2The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms.
- F3The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms.
- F4The RSUs were issued to the reporting person on July 1, 2016, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms.